A recent article provides a comprehensive narrative review of how the understanding, classification, management, and prognostication of traumatic brain injury (TBI) have evolved, while highlighting future directions for improving patient outcomes. Despite extensive research, TBI remains a major global health burden, with high rates of mortality and long-term disability. The authors emphasise that progress in TBI care has been gradual, with increasing recognition of its complexity and heterogeneity.
Historically, TBI classification has relied on the Glasgow Coma Scale (GCS), which categorises injury severity into mild, moderate, or severe based on level of consciousness. While this system has been widely adopted for over five decades, it is now considered overly simplistic and insufficient to capture the diverse pathophysiological processes underlying TBI. Contemporary approaches propose a more comprehensive classification framework that integrates clinical features, imaging findings, biomarkers, and modifiers such as psychosocial factors.
A multidimensional model, referred to as CBI-M, aims to better characterise injury patterns and account for variability in patient trajectories. Increasing attention is also being paid to temporal disease evolution, with early intensive care data and physiological trends improving prognostic accuracy. Biomarkers reflecting astroglial, neuronal, and axonal injury are emerging as valuable tools for diagnosis, monitoring secondary injury, and predicting outcomes, although their routine clinical use remains under development.
Management strategies for TBI have traditionally focused on preventing secondary brain injury, as primary injury is irreversible. Central to this approach is the control of intracranial pressure (ICP) and maintenance of adequate cerebral perfusion pressure (CPP). Current guidelines recommend a tiered approach to ICP management, starting with basic interventions such as positioning and sedation, and escalating to more invasive measures, including cerebrospinal fluid drainage and decompressive craniectomy (DC). Standard CPP targets of 60–70 mmHg are commonly used, alongside assessments of autoregulatory function.
However, the concept of fixed ICP and CPP thresholds is increasingly being challenged. Emerging evidence supports a shift towards physiology-driven, individualised care. Advanced monitoring techniques, including high-frequency signal analysis, allow for continuous assessment of cerebrovascular autoregulation. Indices such as pressure reactivity (PRx) may enable personalised CPP targets, optimising cerebral blood flow based on each patient’s physiology. While promising, these methods are currently limited to specialised centres and require further validation.
Surgical management, particularly decompressive craniectomy, has been refined through landmark trials. Early prophylactic DC has not demonstrated outcome benefits, whereas delayed DC for refractory intracranial hypertension has been associated with reduced mortality and improved long-term outcomes. These findings underscore the importance of timing and patient selection, as well as the recognition that TBI recovery is prolonged and extends beyond the acute phase.
Monitoring cerebral oxygenation has also gained prominence. Measurement of brain tissue oxygen tension (PbtO2) allows clinicians to detect cerebral hypoxia and guide interventions such as increasing oxygen delivery, augmenting CPP, or administering transfusions. Although trials comparing combined ICP and PbtO2-guided therapy with ICP-guided care alone have not consistently shown improved functional outcomes, certain subgroups may benefit. Ongoing studies are expected to clarify the role of PbtO2 monitoring.
In addition, cerebral microdialysis provides insight into brain metabolism by measuring extracellular markers such as glucose, lactate, and pyruvate. While primarily a research tool, it holds potential for guiding personalised therapy when combined with other monitoring modalities.
Recent evidence has also prompted a reassessment of transfusion strategies in TBI. Contrary to the restrictive approaches used in general critical care, studies suggest that more liberal transfusion thresholds may improve neurological outcomes in brain-injured patients. Similarly, advances in ventilatory management and haemodynamic optimisation have contributed to a more holistic approach to critical care, recognising the interplay between systemic physiology and cerebral function.
Prognostication in TBI remains challenging. There has been a shift away from early pessimism towards an appreciation of the uncertainty and potential for recovery, even in severe cases. Data from longitudinal studies demonstrate significant functional improvement over time, with many patients experiencing meaningful recovery up to one year post-injury. Despite this, early withdrawal of life-sustaining treatment remains a major contributor to mortality, often occurring within the first week. This highlights the need for cautious decision-making and improved prognostic tools.
The concept of cognitive motor dissociation (CMD) has further reshaped understanding of consciousness in TBI. CMD describes a state in which patients appear unresponsive behaviourally but retain covert cognitive function detectable באמצעות advanced neuroimaging or electrophysiological techniques. Its presence is associated with better recovery prospects, yet its detection is limited by resource availability and technical complexity.
Looking ahead, artificial intelligence (AI) is expected to play a transformative role in TBI care. By integrating large volumes of multimodal data, AI can enhance patient phenotyping, predict clinical deterioration, and support personalised treatment strategies. Digital twin models, which simulate individual patient physiology, may enable real-time decision support at the bedside. However, challenges such as data standardisation, infrastructure requirements, and regulatory considerations currently limit widespread implementation.
Future research must move beyond single-intervention trials towards multifaceted, individualised treatment strategies. Given the complex and heterogeneous nature of TBI, combining therapies targeting multiple pathophysiological pathways may be more effective.
Source: Journal of Critical Care
Image Credit: iStock
